In this respect, the Iressa rechallenge in advanced NSCLC EGFR-M+ patients who responded to gefitinib used as first-line or previous treatment (ICARUS) trial investigated prospectively the safety and the efficacy of a rechallenge treatment with gefitinib in a cohort of advanced EGFR-mutant NSCLC patients [8]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.